1. Introduction {#s0005}
===============

Progressive multiple sclerosis (PMS) is a chronic, inflammatory, demyelinating disorder with progressive neurodegeneration ([@bb0225]). Inflammation is an inducer of neuronal damage which, with chronic demyelination, leads to loss of central nervous system (CNS) tissue. White matter demyelination is a cardinal hallmark of PMS, although neuropathological studies also indicate extensive axonal loss in the spinal cord tracts and synapses of the gray matter ([@bb0030]; [@bb0110]).

MS has an established link to mitochondrial dysfunction ([@bb0240]). At the cellular level, mitochondrial dysfunction plays a direct role in demyelination, with mitochondrial structural changes, altered gene expression and mitochondrial enzyme activities observed in MS patients ([@bb0135]). At the genetic level, inherited mitochondrial DNA (mtDNA) variation modulates MS risk ([@bb0010]), with mtDNA haplogroups (distinct monophyletic clades of mtDNA variants) both increasing (haplogroup J) ([@bb0230]) and decreasing (haplogroup K) ([@bb0105]) the risk of developing MS. Multiple deletions of mtDNA, typically indicative of primary mitochondrial disease, can be detected in the gray matter of MS cases ([@bb0050]).

In mammals, mtDNA appears more resistant to degradation by nucleases than nDNA ([@bb0130]) and appears to persist in extracellular fluids as circulating, cell-free, mtDNA (ccf-mtDNA). ccf-mtDNA appears associated with neurodegeneration, with significant decreases in ccf-mtDNA observed in the cerebrospinal fluid (CSF) of patients with Parkinson\'s disease (PD) ([@bb0175]) and Alzheimer\'s disease (AD) ([@bb0170]). Conversely, elevated CSF ccf-mtDNA appears associated with traumatic brain injury in children ([@bb0170]) and recent investigations of ccf-mtDNA in MS, focusing on individuals alive at CSF biopsy, identified increased ccf-mtDNA copies in both relapsing-remitting MS (RRMS) ([@bb0235])and PMS ([@bb0120]); with elevated ccf-mtDNA appearing associated with brain atrophy ([@bb0120]).

To date, there are no accurate predictors of neurodegeneration in MS. ([@bb0095]) The identification of markers which could inform neurodegenerative risk would be useful to both existing therapeutic strategies, but could also be used to inform future MS clinical trials ([@bb0095]). Given the links between MS progression and mitochondrial DNA ([@bb0050]; [@bb0045]) and previous evidence linking ccf-mtDNA to other neurodegenerative diseases ([@bb0175]; [@bb0170]), we analysed the ccf-mtDNA present in the post mortem ventricular CSF (vCSF) of PMS cases where neurodegeneration is more pronounced, comparing both ccf-mtDNA abundance and integrity to matched controls. In addition, we assessed the levels of known neurodegenerative disease (glial fibrillary acidic protein and S100 calcium binding protein B) ([@bb0165]; [@bb0245]; [@bb0015]; [@bb0150]) and PMS protein markers (Chitinase 3 like 1 and Chitinase 3 like 2) ([@bb0210]; [@bb0100]), correlating protein levels to ccf-mtDNA copies in both PMS cases and controls. We hypothesised that, similar to other neurodegenerative diseases such as AD and PD, CSF ccf-mtDNA levels would be significantly lower in PMS cases with evidence of neurodegeneration, indicating that a reduction in ccf-mtDNA in the CSF is a component of neurodegenerative disease.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

36 PMS (30% male, mean age at death 63 ± 12 years) and 43 matched control (54% male, mean age at death 78 ± 10 years) ventricular CSF (vCSF) samples were obtained from The UK MS Society Tissue Bank (Imperial College, London). All vCSF samples were prepared (i.e. to remove cells) as described previously ([@bb0175]; [@bb0155]). Briefly, vCSF was centrifuged (2000 *g* for 10 min) at room temperature, aliquoted into CSF collection tubes and stored upright at −80 °C. PMS was diagnosed in-life and confirmed neuropathologically (UK MS Society Tissue Bank, Imperial College, London). All controls were negative for the hallmarks of disease-related neurodegeneration or inflammation. Importantly, we saw no significant differences in age at death, brain weight post mortem interval or male:female ratio between PMS cases and controls, summarised in Supplementary Table 1.

2.2. mtDNA copy and deletion quantification {#s0020}
-------------------------------------------

Mitochondrial DNA was quantified using established methods (previously described in ([@bb0175]; [@bb0085]; [@bb0190]). Briefly, two mitochondrial regions, *MTND1*, *MTND4* (Supplementary Fig. 2) and a nuclear encoded housekeeping gene, *B2M*, were amplified and assayed in triplicate by multiplex Taqman mediated qPCR as per manufacturer\'s guidelines (ThermoFisher Scientific, primers: *MTND1* forward 5′-ACGCCATAAAACTCTTCACCAAAG-3′ and reverse 5′-GGGTTCATAGTAGAAGAGCGATGG-3′, *MTND4* forward 5′-ACCTTGGCTATCATCACCCGAT-3′ and reverse: 5′-AGTGCGATGAGTAGGGGAAGG-3′, and B2M forward 5′-CACTGAAAAAGATGAGTATGCC-3′ and reverse 5′- AACATTCCCTGACAATCCC-3′). As in previous work ([@bb0065]), mtDNA primer efficiency and specificity was assessed as accurate after zero amplification of DNA from Rho0 (mtDNA depleted) cell lines, avoiding the unintended amplification of nuclear pseudogenes. mtDNA level is calculated as an absolute measurement of *MTND1* derived from a triplicated standard curve and is expressed as copies per 1 μl of CSF. mtDNA deletion level, expressed as a ratio of *MTND1* to *MTND4* as described previously ([@bb0175]; [@bb0085]; [@bb0190]). mtDNA deletions, as in previous work ([@bb0085]), were limited to those \>10%; to account for the sensitivity and specificity of qPCR to reliably detect mtDNA deletions.

2.3. mtDNA deep-sequencing {#s0025}
--------------------------

Deep sequencing and subsequent bioinformatic analysis of mtDNA extracted from a subset of vCSF samples (12 PMS and 22 controls, 41% of samples) was performed as previously described ([@bb0065]). Briefly, DNA was extracted from vCSF using Ultrapure™ (phenol:chloroform:isoamyl alcohol) and ethanol precipitation as per manufacturer\'s instructions (SigmaAldritch). mtDNA was enriched using three overlapping long-range PCR amplicons covering the entire mtDNA genome (set 1, m.3016-9201, forward 5′-CAGCCGCTATTAAAGGTTCG-3′ and reverse: 5′-GTTGTCGTGCAGGTAGAGG-3′; set 2, m.8656-14,857, forward 5′-ACCACCCAACAATGACTAATC-3′ and reverse 5′-GGTTGTTTGATCCCGTTTCG-3′, and set 3, m.14797-3574, forward 5′-ATTCATCGACCTCCCCACC-3′ and reverse: 5′-GGAGGGGGGTTCATAGTAG-3′) and was amplified using PrimeSTAR GXL DNA Polymerase as per manufactures guidelines (Takara Bio Company). As in previous work ([@bb0065]), mtDNA primer efficiency and specificity was assessed as accurate after zero amplification of DNA from Rho0 (mtDNA depleted) cell lines, avoiding the unintended amplification of nuclear pseudogenes. In 59% (47 out of 81) of vCSF samples, mtDNA enrichment was hindered by low mtDNA template availability. Subsequent PCR products were purified, pooled and prepared using Illumina Nextera XT Library preparation kit using manufacturers guidelines (Illumina, USA). Libraries were pooled using the MiSeq Reagent Kit and the Illumina MiSeq v3.0 sequencing platform (Illumina, USA) in paired-end, 250 bp reads. Post-run FASTQ files were analysed using an established bioinformatic pipeline as previously described ([@bb0065]). Homoplasmic variation was defined as \>99% Heteroplasmic variation was defined as \>1% and \< 99%. Variant comparisons, i.e. mutational burden were made between PMS case and control CSF ccf-mtDNA.

2.4. Protein quantification {#s0030}
---------------------------

Glial fibrillary acidic protein (GFAP) and S100 calcium binding protein B (S100β), previously used to indicate neurodegeneration ([@bb0165]; [@bb0245]), and PMS ([@bb0015]; [@bb0150]) were measured in all samples with sufficient vCSF (27 PMS and 15 controls, 51% of samples) using western blot, with protein levels normalised to total protein level measured with BLOT-FastStain™. Chitinase 3 like 1 (CHI3L1), used to differentiate active and inactive PMS ([@bb0210]), and Chitinase 3 like 2 (CHI3L2), used to differentiate PMS and RRMS ([@bb0100]), were measured by ELISA (Cusabio, YKL-40 and R&D systems DC3 L10, respectively) in the same samples as above (i.e. 27 PMS and 15 controls) as per manufacturers guidelines.

2.5. Statistical analysis {#s0035}
-------------------------

Data was analysed using SPSS v22 and Prism v5 using data appropriate tests (detailed in the text). Statistical significance was set at *p* \< .05. Heteroplasmic Ka/Ks is expressed as a ratio of non-synonymous (Ka) to synonymous (Ks) heteroplasmic variants ([@bb0125]).

3. Results {#s0040}
==========

a)Analysis of vCSF ccf-mtDNA in PMS

Similar to our previous work ([@bb0175]), and the work of others ([@bb0170]; [@bb0235]; [@bb0120]), we limited our analysis to samples harbouring \<1 copy of a housekeeping gene (*B2M*) to minimise the perceived contamination of cells or cellular debris in the vCSF; reducing our cohort to 14 PMS cases (38%) and 25 controls (58%). Using these criteria we identified a significant reduction of vCSF ccf-mtDNA level in PMS cases compared to controls (Wilcoxon Ranked Sum Test *p* = .013, mean rank ccf-mtDNA in 14 PMS cases was 16.4 and in 25 controls was 26.9, [Fig. 1](#f0005){ref-type="fig"}a).Fig. 1Comparison of ccf-mtDNA copies between PMS cases and controls. The plots depict the comparison of ccf-mtDNA copies (per μl vCSF) between PMS cases (shaded) and matched controls (unshaded): a) with a B2M threshold of \<1 copy applied (where mean ccf-mtDNA copies in 14 PMS cases was 1678.0, SEM of 298.4, and 2876.2, SEM of 317.0, in 25 controls) and, b) without a B2M threshold applied (where mean ccf-mtDNA copies in 36 PMS cases was 2412.7, SEM of 327.5, and 3784.7, SEM of 356.4, in 43 controls), where \*\* and \*\*\* indicate Wilcoxon Ranked Sum Test significance at *p* \< .05 and *p* \< .005 respectively.Fig. 1

However, recent reports show evidence of cell free-nuclear DNA (ccf-nDNA) in the CSF ([@bb0005]; [@bb0055]), suggesting that nDNA contamination may not necessarily be a result of carryover of cells or a product of cellular debris during DNA extraction. In addition, the existing literature suggests that ccf-mtDNA resists degradation whilst ccf-nDNA does not ([@bb0130]), raising the possibility that ccf-nucleic acids are still a consequence of cellular degradation, but whilst the ccf-nDNA has been degraded, the ccf-mtDNA has persisted. Therefore we removed the *B2M* threshold from our analysis, continuing to identify a significant decrease of vCSF ccf-mtDNA copies in PMS cases compared to controls (Wilcoxon Ranked Sum Test *p* = .0023, mean rank ccf-mtDNA in 36 PMS cases was 30.4 and in 43 controls was 45.8, [Fig. 1](#f0005){ref-type="fig"}b).

To investigate further, we tested the effect of *B2M* level on ccf-mtDNA level in PMS using logistic regression, confirming our previous association between PMS and ccf-mtDNA when including *B2M* level as a covariate (*p* = .004), identifying no significant correlation between *B2M* levels and ccf-mtDNA levels (r^2^ = 2.5 × 10^−7^ and *p* = 99, Supplementary Fig. 1) and no significant difference in *B2M* levels between PMS cases and controls (Wilcoxon Ranked Sum Test *p* \> .05).

Given that *B2M* levels do not appear to effect ccf-mtDNA abundance, and to increase sample size and statistical power, all subsequent analysis will refer to the full dataset (36 PMS cases and 43 controls). Linear regression showed no significant association (*p* \> .05) between ccf-mtDNA and age at death, brain weight, post mortem interval (in PMS cases, controls or combined) or age of onset and disease duration (PMS cases only), and we found no significant association (Logistic regression p \> .05) between ccf-mtDNA and sex (in PMS cases, controls or combined, summarised in Supplementary Table 2).b)ccf-mtDNA integrity in PMS vCSF

mtDNA deletions have been observed in PMS neuronal tissue ([@bb0050]). We were able to identify mtDNA deletions (\>10% deleted mtDNA) ([@bb0085]) in a minority of our samples (5 out of 36, or 13%, PMS cases and 9 out of 43, or 20%, controls), indicating that ccf-mtDNA is intact in the majority of samples (Supplementary Fig. 2). However we found no significant difference in ccf-mtDNA deletion levels between PMS cases and controls (Wilcoxon Ranked Sum Test *p* \> .05, [Fig. 2](#f0010){ref-type="fig"}a) and no significant correlation (p \> .05) between ccf-mtDNA deletion level and age at death, brain weight, post mortem interval (in either PMS cases, controls or when combined) or age of onset (PMS cases only) (Supplementary Table 2).Fig. 2Analysis of ccf-mtDNA integrity in PMS cases and controls. The plots depict: a) comparative ccf-mtDNA deletions (\>10%) detected in PMS cases and matched controls (mean deletion in 5 PMS cases was 16.8, SEM of 4.2, and 20.5, SEM of 2.8, in 9 controls), b) the comparative total heteroplasmic mutation frequency (heteroplasmy per bp sequenced) in PMS cases and controls (mean total heteroplasmic mutation frequency in 12 PMS cases was 2.6 × 10^−3^, SEM of 7.1 × 10^−4^, and 2.2 × 10^−3^, SEM of 4.3 × 10^−4^, in 22 controls). c) total heteroplasmic mutation frequency versus ccf-mtDNA copies for PMS cases and matched controls combined (12 PMS cases and 22 controls), and d) the comparative Ka/Ks for PMS cases and matched controls (mean Ka/Ks in 12 PMS cases was 1.9, SEM of 0.28, and 0.99, SEM of 0.17, in 22 controls), where \*\*\* indicates Wilcoxon Ranked Sum Test significance at *p* \< .005.Fig. 2

Next generation sequencing of ccf-mtDNA identified heteroplasmic variation in all 34 vCSF samples used. Although mutation frequency appeared higher in PMS cases compared to controls, the comparison was not significant (Wilcoxon Ranked Sum Test *p* \> .05, mean and standard deviation of total heteroplasmic mutation frequency in 12 PMS cases was 1.6 × 10^−3^ ± 9 × 10^−4^ and 1.4 × 10^−3^ ± 1 × 10^−3^ in 22 controls, [Fig. 2](#f0010){ref-type="fig"}b and Supplementary Table 3).

Further stratification by variant type (e.g. D-loop variants, tRNA variants etc) revealed an increase in non-synonymous variation (mean heteroplasmic non-synonymous mutation frequency in PMS cases was 1.1 × 10^−3^and was 7.4 × 10^−4^ in controls) and a decrease in synonymous variation (mean heteroplasmic non-synonymous mutation frequency in PMS cases was 5.x10^−4^and was 9.7 × 10^−4^ in controls) between PMS cases and controls, although no comparison reached statistical significance (*p* \> .05, Supplementary Fig. 3 and Supplementary Table 3).

Under the hypothesis that ccf-mtDNA export may be a product of normal mtDNA maintenance, we compared total heteroplasmic variation frequency to ccf-mtDNA level, but found no significant correlation (p \> .05, [Fig. 2](#f0010){ref-type="fig"}c). Further, we found no significant correlation between total heteroplasmic mutation burden and age at death, brain weight, post mortem interval (in either PMS cases, controls or when combined) or age of onset (PMS cases only), summarised in Supplementary Table 2.

We did identify a significant difference in heteroplasmy Ka/Ks ratio, a correction used as an estimate of the degree of evolutionary constraint ([@bb0125]), between PMS cases and controls (Wilcoxon Ranked Sum Test *p* = .0022, [Fig. 2](#f0010){ref-type="fig"}d); with PMS ccf-mtDNA having a higher proportion of non-synonymous to synonymous variation compared to controls. However, we found no significant correlation (*p* \> .05) between Ka/Ks ratio and ccf-mtDNA level in either PMS cases, controls or when combined and no correlation between Ka/Ks ratio and age at death, brain weight, post mortem interval (in either PMS cases, controls or when combined) or age of onset (PMS cases only), summarised in Supplementary Table 2.c)ccf-mtDNA and neurodegeneration

Increased S100β is indicative of neurodegeneration ([@bb0205]) and vCSF levels were significantly higher in PMS cases versus controls, (Wilcoxon Ranked Sum Test *p* = .040, mean and standard deviation in PMS cases was 0.99 ± 1.0 and 0.17 ± 0.48 in controls ([Fig. 3](#f0015){ref-type="fig"}a and Supplementary Table 4), with 14 out of 27 PMS cases (51%) and 12 out of 15 controls (80%) exhibiting undetectable levels.Fig. 3Comparison of neurodegenerative protein levels between PMS cases and controls. The plots depict the comparative levels of the neurodegenerative proteins S100β, GFAP, CHI3L1 and CHI3L2 (a to d) detected in 27 PMS cases and 15 controls and e) the relative ratio of CHI3L1 to CHI3L2 in PMS cases and controls, where \*\* indicates Wilcoxon Ranked Sum Test significance at *p* \< .05.Fig. 3

Increased CSF levels of GFAP is indicative of neurodegeneration ([@bb0165]) and increased levels have been observed on PMS patients ([@bb0015]). We observed an increase of GFAP in PMS cases compared to control ([Fig. 3](#f0015){ref-type="fig"}b), although this did not reach statistical significance (Wilcoxon Ranked Sum Test *p* \> .05, mean and standard deviation in PMS cases was 0.53 ± 0.0.90 and 0.16 ± 0.22 in controls), with 11 out of 27 PMS cases (41%) and 6 out of 15 controls (40%) exhibiting undetectable levels.

CSF CHI3L1 and CHI3L1 are elevated in PMS compared to controls ([@bb0100]), with CHI3L1:CHI3L2 ratio reportedly having superior predictive accuracy than individual measures ([@bb0100]). However, neither CHI3L1, CHI3L2 nor CHI3L1:CHI3L2 ratio were significantly different between PMS cases and matched controls when analysed together or as a ratio (Wilcoxon Ranked Sum Test p \> .05, [Figs. 3](#f0015){ref-type="fig"}c-e and Supplementary Table 4).

However, ultimately, we saw no significant correlation between vCSF ccf-mtDNA and the levels of S100β, GFAP, CHI3L1, CHI3L2 or CHI3L1:CHI3L2 ratio when analysed as PMS cases only or controls only, or when combined (Supplementary Table 2).

4. Discussion {#s0045}
=============

Our results indicate that vCSF ccf-mtDNA is significantly reduced in post-mortem PMS cases compared to controls which, when taken into context with observations in both Parkinson\'s disease (PD) ([@bb0175]) and Alzheimer\'s disease (AD) ([@bb0170]), supports our hypothesis that ccf-mtDNA may be an component of neurodegeneration. After assessing mtDNA integrity, we conclude that ccf-mtDNA is largely intact, with few cases and controls harbouring mtDNA deletions. Interestingly we did observe a shift in the proportion of non-synonymous variation in the ccf-mtDNA of PMS cases compared to controls, which may be a product of ccf-mtDNA export, but which did not correlate to PMS or PMS-related phenotypic data. Ultimately, however, neither ccf-mtDNA level nor integrity correlated to protein markers of neurodegeneration.

Despite our observations, and an increasing amount of literature reporting associations between ccf-mtDNA levels and disease (\>25 publications since 2014, PubMed keyword search using combinations of 'cell' 'free' 'mitochondrial' 'DNA' and appropriate abbreviations), we know little of the underlying causes of mtDNA export to intracellular spaces, therefore we opted to study the integrity of the ccf-mtDNA, contrasting PMS cases to controls.

It is possible that, assuming that mtDNA export is a normal procedure (as it occurs in control samples and typically at higher levels) ([@bb0175]; [@bb0170]; [@bb0145]), the lower levels seen in neurodegenerative disease is a direct consequence of a pre-existing cellular mtDNA depletion in vulnerable brain regions. This hypothesis is supported by previous studies showing tissue specific depletion of mtDNA in PD patients, ([@bb0180]; [@bb0090]) AD patients ([@bb0195]; [@bb0200]), and MS patients ([@bb0140]; [@bb0070]; [@bb0020]; [@bb0035]); indicating that low ccf-mtDNA observed in the vCSF of these cases is possibly a result of neuronal mtDNA levels which are already compromised prior to export.

Alternatively, it is possible that the release of mtDNA into intracellular spaces is a quality control mechanism, where mutant mtDNA is expelled to maintain mitochondrial function. This hypothesis is supported by recent neuronal work in *C. elegans*, which expel dysfunctional mitochondria when exposed to neurotoxic stress ([@bb0145]). Further, the ependymal epithelium of the ventricles and choroid plexus have abundant mitochondrial content due to the high energy demand of transepithelial transport ([@bb0060]). The majority of these mitochondria are located at the apical brush border ([@bb0220]), the most likely site of expulsion of whole mitochondria or cell-free mtDNA into the CSF during normal cell turnover or through active vesicular transport. Our data appear to support this hypothesis in part. Our investigations indicate that vCSF ccf-mtDNA is predominantly intact, with few samples showing measurable deletion levels, and although NGS analysis indicates the presence of heteroplasmic variation, we observed a non-significant increase in total heteroplasmic mutation and non-synonymous burden between PMS cases and controls. We did observe an imbalance in the Ka/Ks ratio between PMS cases and controls, with PMS cases exhibiting a greater than expected ratio of non-synonomous:synonymous variation, which may indicate that ccf-mtDNA export may be a selective process; where the 'wild-type' mtDNA molecule is retained in the cell and the 'mutant' mtDNA molecule is preferentially exported. This hypothesis supported by recent work in MS indicating that the neuronal tissues of cases harbour relatively few mtDNA mutations compared to matched controls ([@bb0040]),although further work would be needed to be definitive.

Contrary to our findings, increased levels of ccf-mtDNA have been observed in the CSF of both RRMS ([@bb0235]) and PMS ([@bb0120]). This is perhaps not unexpected in RRMS, which is an acutely inflammatory disease which precedes the neurodegenerative processes characteristic of PMS ([@bb0115]). It is possible therefore, that the increase in ccf-mtDNA observed in RRMS is a direct result of an increase in inflammatory cells which, in addition to nuclear DNA, release mtDNA into the CSF ([@bb0075]).

Leur\'s et al. (2018) ([@bb0120]) report an increase of lumbar CSF (lCSF) ccf-mtDNA in PMS cases compared to controls. Given the parity in cohort sizes (40 PMS and 23 controls to our 36 PMS and 43 controls) the discrepancy between our results is unlikely to be a factor of statistical power. It is possible that the difference in CSF sampling may explain the discordance between results, with their samples taken in-life and ours taken post-mortem, and as the composition of vCSF may be different from lCSF in normal circumstances and under severe pathological conditions ([@bb0080]; [@bb0215]). However we observed no correlation between post mortem interval or brain weight to ccf-mtDNA levels in either PMS cases, controls or the cohorts combined, suggesting that the latter is not the case. Further, the increase in PMS ccf-mtDNA reported by Leurs et al. (2018) ([@bb0120]) is limited to a small proportion of PMS cases (\~30%) and the majority of PMS cases and controls exhibited ccf-mtDNA copies below the levels we observed in our study and other previously published lCSF mtDNA levels (typically 20--400 copies per microliter CSF in cases and 20--300 copies per microliter in controls in previous reports) ([@bb0170]; [@bb0145]; [@bb0185]). Our overall comparably higher ccf-mtDNA levels could be attributed to the increased autolysis or pleoctytosis which occurs in post-mortem CSF ([@bb0160]; [@bb0025]), however we observed a significant reduction in ccf-mtDNA copies in PMS cases, despite no significant difference in PMI, brain weight or B2M levels between PMS cases and controls and no correlation between ccf-mtDNA and ccf-B2M levels, suggesting that this is not the case. It should be noted that, unlike Leurs et al. (2018) ([@bb0120]), we were unable to assess the effect of ccf-mtDNA on brain atrophy directly.

With the exception of S100β, protein markers of neurodegeneration and PMS appeared uninformative when comparing cases and controls. Although GFAP and CHI3L1 appeared elevated in PMS cases compared to controls, the differences did not reach statistical significance. Further, we observed no obvious stratification of PMS cases using CHI3L1:CHI3L2 ratio, further indication that our cases were indeed all PMS cases ([@bb0100]).Never the less, we observed no correlation between protein markers of neurodegeneration and ccf-mtDNA level or integrity; although this may reflect the late disease stage of our cases and the use of post-mortem CSF.

5. Conclusion {#s0050}
=============

In conclusion, and excepting limitations, our findings support our hypothesis that decreased ccf-mtDNA may be an indicator of neurodegeneration in PMS. Although we observed a significant association, we urge caution. In light of previous work ([@bb0235]; [@bb0120]), we cannot exclude the possibility that ccf-mtDNA levels rise in-life in response to the onset of disease and then reduce as neurodegeneration increases, however longitudinal assessments in PMS cases would be needed to assess this. Therefore, whilst reduced ccf-mtDNA may be a hallmark of the presence of neurodegeration, it is not particularly useful as a biomarker, even with a more detailed analysis.
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